A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Patients with Newly-Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)

Principal Investigator

Connor Sweeney

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1012542